Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 8,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Age-related Macular Degeneration, Diabetic Retinopathy, Hypertensive Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion
Interventions: Phase variance optical coherence tomography (PV-OCT); Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alcohol Drinking, Binge Drinking, Text Messaging
Interventions: Brief Alcohol Intervention, Automated and Targeted Text Messages; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Epilepsy
Interventions: Eslicarbazepine acetate; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 4 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Henderson, Nevada

Conditions: Healthy Infant Nutrition
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 4 Months to 9 Months
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hemophilia A
Interventions: efanesoctocog alfa (BIVV001); Drug
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: Not listed
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • San Diego, California • Gainesville, Florida + 12 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV (GSK3389245A) low dose formulation vaccine, RSV (GSK3389245A) middle dose formulation vaccine, RSV (GSK3389245A) high dose formulation vaccine, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 23 Months
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Anaheim, California • Aurora, Colorado • Topeka, Kansas + 3 more

Conditions: Lupus Nephritis
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Macular Neovascularization Secondary to Age-Related Macular Degeneration
Interventions: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL); Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 90
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 78 more

Conditions: Diabetes, Kidney Diseases
Interventions: Continuous Glucose Monitoring; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Great Neck, New York

Conditions: Disease Type and/or Category Not Applicable
Interventions: Omnilux; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: Montelukast, Prednisone; Drug
Lead sponsor: Hal C Charles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cystic Fibrosis
Interventions: Placebo, Tobi Podhaler; Drug · Device
Lead sponsor: Mylan Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 9
States / cities: Miami, Florida • Orlando, Florida • Pensacola, Florida + 4 more

Conditions: Writer's Cramp, Healthy Volunteers, Cervical Dystonia
Interventions: TMS; Device
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Aging, Accidental Falls
Interventions: Cranial Nerve Non-Invasive Neuromodulation, Sham Cranial Nerve Non-Invasive Neuromodulation; Device · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 95 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Obesity
Interventions: Intensive behavioral therapy for obesity; Behavioral
Lead sponsor: University of Southern Mississippi; Other
Eligibility: 25 Years to 50 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Hattiesburg, Mississippi

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Macular Degeneration
Interventions: rhuFab V2 (ranibizumab); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Pneumococcal Vaccines
Interventions: 31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 1,015 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 25
States / cities: Mobile, Alabama • Phoenix, Arizona • Hollywood, Florida + 22 more

Conditions: Breast, Breast Cancer
Interventions: pegfilgrastim; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2041
U.S. locations: 2
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina

Conditions: Infections, Meningococcal
Interventions: Meningococcal vaccine GSK134612; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 14
States / cities: Antioch, California • Daly City, California • Fremont, California + 9 more

Conditions: SARS-CoV-2, Influenza
Interventions: mRNA-1083, Placebo, Influenza Vaccine, COVID-19 Vaccine; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 8,061 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 146
States / cities: Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 122 more

Conditions: Atrial Fibrillation
Interventions: Apixaban, Acetylsalicylic acid; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 50 Years and older
Enrollment: 6,421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 69
States / cities: Mobile, Alabama • Tucson, Arizona • Anaheim, California + 62 more

Conditions: Mental Health Strategies, School Mental Health Services, Digital Technologies, Technology Development
Interventions: ASSIST-MH; Other
Lead sponsor: 3-C Institute for Social Development; Industry
Eligibility: 12 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pediatric Epileptic Syndrome, Partial-onset Seizures
Interventions: Perampanel Oral Suspension, Perampanel Tablet; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 1 Month to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 12 more

Search by objective public record fields.

Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging

Text-Based Messaging Strategies for Preventing Subsequent Problematic Alcohol Use

A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug

Baylor Infant Biomarker of Nutrition Study

Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease

Effectiveness of Light for Enhancement of Cognition by Transcranial Repeated Application (ELECTRA)

Ventilatory Heterogeneity in Participants With Asthma (MK-0476-513)

Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules

Propensity to Develop Plasticity in the Parieto-Motor Networks in Dystonia From the Perspective of Abnormal High-Order Motor Processing

Enhanced Gait and Balance Training

Telenutrition Center: Examining the Implementation of Behavioral Therapy for Obesity

Effect of Body Composition and Metabolism on Oocyte Gene Expression

A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

A Phase III Study of Apixaban in Patients With Atrial Fibrillation

Assist MH Digital Technologies to Support School Mental Health Care

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy